Erratum: Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: Subanalysis of the CASE-J study (Hypertension Research (2009) 32 (505-512) DOI: 10.1038/hr.2009.44);Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: Subanalysis of the CASE-J Study

Hypertension Research

Volumn 32, Issue 6, 2009, Pages 505-512

  Saruta, Takao ^a   Hayashi, Koichi ^a   Ogihara, Toshio ^b   Nakao, Kazuwa ^c   Fukui, Tsuguya ^d   Fukiyama, Kohshiro ^e  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^e Japan Seaman's Relief Association Moji Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CANDESARTAN; CREATININE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SUDDEN DEATH; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; TETRAZOLES;

EID: 68249133888     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.181     Document Type: Erratum

References (36)

1. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcome in the elderly. Kidney Int 2003; 63: 1121-1129.
2. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcome in the community. J Am Coll Cardiol 2003; 41: 47-55.
3. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-1474.
4. Lysaght MJ. Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 2002; 13(Suppl 1): S37-S40.
5. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population: The Hisayama Study. Kidney Int 2005; 68: 228-236.
6. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69 1264-1271.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
8. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006; 17: 2034-2047.
9. The Japanese Society of Nephrology. Clinical Practical Guidebook for Diagnosis and Treatment of Chronic Kidney Disease. Nippon Jinzo Gakkai Shi 2007; 49: 755-870.
10. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43: 1-290.
11. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, Ura N, Kiyohara Y, Hirakata H, Moriyama T, Ando Y, Nitta K, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007; 11: 156-163.
12. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23: S9-S17.
13. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl M, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 851-860.
14. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. RENAAL Study Investigators, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 861-869.
15. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergre J, Yusuf S, Pocock S, CHARM Investigators and Committee. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-766.
16. de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G. Clinical significance of renal function in hypertensive patients at high risk: Results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459-2464.
17. Hayashi K, Kumagai H, Saruta T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003; 16: 116-122.
18. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller III ER, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright Jr JT, Xu S, African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001; 285: 2774-2776.
19. Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, Fukushima M, Sakamoto J, Morita S, Ogihara T, Fukiyama K, Fujishima M, Saruta T, CASE-J Study Group. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: Rationale, design, and methods. Hypertens Res 2003; 26: 979-990.
20. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51: 393-398.
21. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24 613-634.
22. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
24. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28: 1462-1536.
25. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH2004). Hypertens Res 2006; 29 (Suppl): S1-S105.
26. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
27. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140.
28. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation 2007; 116: 85-97.
29. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 2001; 358: 2113-2117.
30. De Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gomez-Campdera F, Luno J. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: Effects of angiotensin II blockade. J Am Soc Nephrol 2006; 17: S206-S212.
31. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2004; 45: 275-280.
32. De Courten M, Ferrari P, Schneider M, Bohlen L, Shaw S, Riesen W, Heynen G, Weidmann P. Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur J Clin Pharmacol 1993; 44: 457-462.
33. Harano Y, Kageyama A, Hirose J, Asakura Y, Yokota T, Ikebuchi M, Suzuki M, Omae T. Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism 1995; 44: 315-319.
34. Koh KK, Quon MJ, Han SH, Chung WJ, Kim JA, Shin EK. Vascular and metabolic effects of candesartan: Insights from therapeutic interventions. J Hypertens 2006; 24 (Suppl): S31-S38.
35. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002; 288: 2981-2997.
36. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.